|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
EP2360165A3
(de)
*
|
2004-03-16 |
2012-01-04 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
CN101238112A
(zh)
*
|
2005-09-08 |
2008-08-06 |
贝林格尔·英格海姆国际有限公司 |
1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-(4-乙炔基-苄基)-苯的晶形、其制备方法及其用于制备药物中的用途
|
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
CN102838599A
(zh)
|
2006-05-04 |
2012-12-26 |
贝林格尔.英格海姆国际有限公司 |
多晶型
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
CA2656847A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
|
US7858587B2
(en)
*
|
2006-09-21 |
2010-12-28 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
|
|
EP2086991A1
(en)
*
|
2006-10-27 |
2009-08-12 |
Boehringer Ingelheim International GmbH |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
|
JP2010519273A
(ja)
|
2007-02-21 |
2010-06-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
PE20090938A1
(es)
*
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
CN101801371B
(zh)
|
2007-09-10 |
2012-11-28 |
詹森药业有限公司 |
可用作sglt抑制剂的化合物的制备方法
|
|
JP5498392B2
(ja)
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
|
|
ES2541141T3
(es)
*
|
2008-01-31 |
2015-07-16 |
Astellas Pharma Inc. |
Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
WO2010009243A1
(en)
|
2008-07-15 |
2010-01-21 |
Theracos, Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
MX2011002166A
(es)
|
2008-08-28 |
2011-04-07 |
Pfizer |
Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
|
|
CN102143965A
(zh)
|
2008-09-08 |
2011-08-03 |
贝林格尔.英格海姆国际有限公司 |
吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
|
|
BRPI0919288A2
(pt)
|
2008-09-10 |
2015-12-15 |
Boehring Ingelheim Internat Gmbh |
teriapia de combinação para tratamento de diabetes e condições relacionadas.
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
AU2009333559B2
(en)
|
2008-12-09 |
2015-03-12 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
EA022310B1
(ru)
|
2008-12-23 |
2015-12-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Солевые формы органического соединения
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
MX345494B
(es)
*
|
2009-02-13 |
2017-02-02 |
Boehringer Ingelheim Int Gmbh * |
Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente.
|
|
UY32427A
(es)
*
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
MY161472A
(en)
*
|
2009-02-13 |
2017-04-14 |
Boehringer Ingelheim Int |
Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
PL2395983T3
(pl)
*
|
2009-02-13 |
2020-09-07 |
Boehringer Ingelheim International Gmbh |
Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
|
|
AU2016213789B2
(en)
*
|
2009-02-13 |
2018-01-18 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
PT2414363E
(pt)
|
2009-03-31 |
2014-02-26 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
KR101532412B1
(ko)
|
2009-07-10 |
2015-06-29 |
얀센 파마슈티카 엔.브이. |
1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
|
|
WO2011035250A1
(en)
|
2009-09-21 |
2011-03-24 |
Gilead Sciences, Inc. |
Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
|
|
BR112012007085B8
(pt)
|
2009-09-30 |
2021-05-25 |
Boehringer Ingelheim Int |
processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
|
|
HUE029381T2
(en)
|
2009-09-30 |
2017-02-28 |
Boehringer Ingelheim Int |
Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
|
SG10201500258WA
(en)
|
2009-10-14 |
2015-03-30 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
NZ599945A
(en)
|
2009-11-02 |
2014-05-30 |
Pfizer |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
|
NZ599298A
(en)
|
2009-11-27 |
2014-11-28 |
Boehringer Ingelheim Int |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US20140088027A1
(en)
|
2010-03-30 |
2014-03-27 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
|
WO2011138421A1
(en)
|
2010-05-05 |
2011-11-10 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
|
LT2568988T
(lt)
|
2010-05-11 |
2016-09-12 |
Janssen Pharmaceutica, N.V. |
Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
|
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
NZ603319A
(en)
|
2010-06-24 |
2015-04-24 |
Boehringer Ingelheim Int |
Diabetes therapy
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
|
UA110347C2
(uk)
|
2010-08-12 |
2015-12-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
BR112013010021A2
(pt)
|
2010-11-02 |
2019-09-24 |
Boehringer Ingelheim Int |
combinações farmacêuticas para o tratamento de distúrbios metabólicos.
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
|
AU2012241897C1
(en)
|
2011-04-13 |
2017-05-11 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of SGLT2
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
EA201301354A1
(ru)
|
2011-06-03 |
2014-05-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2841552C
(en)
|
2011-07-15 |
2020-06-23 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
JP2015516404A
(ja)
|
2012-05-09 |
2015-06-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
代謝疾患の処置のための合剤
|
|
US20130303554A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in sirs and/or sepsis
|
|
EP3685839A1
(en)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin for use in the treatment of albuminuria and kidney related diseases
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
EP4245765A3
(en)
|
2013-04-04 |
2024-03-20 |
Boehringer Ingelheim Vetmedica GmbH |
Treatment of metabolic disorders in equine animals
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HRP20190101T1
(hr)
|
2013-04-05 |
2019-03-08 |
Boehringer Ingelheim International Gmbh |
Terapeutske uporabe empagliflozina
|
|
KR102309654B1
(ko)
|
2013-04-18 |
2021-10-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
약제학적 조성물, 치료 방법 및 이의 용도
|
|
US9394329B2
(en)
|
2013-09-27 |
2016-07-19 |
Sunshine Lake Pharma Co., Ltd. |
Glucopyranosyl derivatives and their uses in medicine
|
|
ES2969764T3
(es)
|
2013-12-17 |
2024-05-22 |
Boehringer Ingelheim Vetmedica Gmbh |
Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
|
|
CN115282284A
(zh)
*
|
2014-01-23 |
2022-11-04 |
勃林格殷格翰动物保健有限公司 |
犬科动物中代谢紊乱的治疗
|
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
|
ES2811261T3
(es)
|
2014-04-01 |
2021-03-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabólicos en animales equinos
|
|
CN103965020B
(zh)
*
|
2014-05-06 |
2015-09-09 |
启东东岳药业有限公司 |
制备5-碘-2-溴苄醇的方法
|
|
TWI733652B
(zh)
|
2014-07-11 |
2021-07-21 |
美商基利科學股份有限公司 |
用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
|
|
JP2017526730A
(ja)
|
2014-09-16 |
2017-09-14 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｔｏｌｌ様受容体モジュレーターの固体形態
|
|
HUE068152T2
(hu)
|
2014-09-25 |
2024-12-28 |
Boehringer Ingelheim Vetmedica Gmbh |
SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
|
|
TWI740546B
(zh)
*
|
2014-10-29 |
2021-09-21 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
HK1249847A1
(zh)
|
2015-03-09 |
2018-11-16 |
Intekrin Therapeutics, Inc. |
用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
|
|
MX389367B
(es)
|
2015-08-27 |
2025-03-20 |
Boehringer Ingelheim Vetmedica Gmbh |
Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
HRP20220355T1
(hr)
|
2015-09-16 |
2022-05-13 |
Gilead Sciences, Inc. |
Postupci za liječenje infekcija coronaviridae
|
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
|
CA3039745A1
(en)
|
2016-11-10 |
2018-05-17 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CN116036112A
(zh)
|
2017-03-14 |
2023-05-02 |
吉利德科学公司 |
治疗猫冠状病毒感染的方法
|
|
KR20200036808A
(ko)
|
2017-04-03 |
2020-04-07 |
코히러스 바이오사이언시스, 인크. |
진행성 핵상 마비 치료를 위한 PPARγ 작용제
|
|
WO2018204198A1
(en)
|
2017-05-01 |
2018-11-08 |
Gilead Sciences, Inc. |
Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
|
EP4512475A3
(en)
|
2017-07-11 |
2025-05-14 |
Gilead Sciences, Inc. |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
KR20220011685A
(ko)
|
2019-05-22 |
2022-01-28 |
길리애드 사이언시즈, 인코포레이티드 |
Tlr7 조절 화합물과 hiv 백신의 조합
|
|
CN114727624A
(zh)
|
2019-11-28 |
2022-07-08 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂在非人哺乳动物的停奶中的用途
|
|
AU2021214911A1
(en)
|
2020-01-27 |
2022-07-21 |
Gilead Sciences, Inc. |
Methods for treating SARS CoV-2 infections
|
|
KR20220143732A
(ko)
|
2020-02-17 |
2022-10-25 |
베링거잉겔하임베트메디카게엠베하 |
고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
|
|
CN115209894B
(zh)
|
2020-03-06 |
2025-05-02 |
弗特克斯药品有限公司 |
治疗apol-1依赖性局灶节段性肾小球硬化的方法
|
|
CN118994170A
(zh)
|
2020-03-12 |
2024-11-22 |
吉利德科学公司 |
制备1'-氰基核苷的方法
|
|
EP4132651B1
(en)
|
2020-04-06 |
2026-03-18 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
|
ES3041698T3
(en)
|
2020-05-29 |
2025-11-13 |
Gilead Sciences Inc |
Remdesivir for the treatment of viral infections
|
|
CA3187821A1
(en)
|
2020-06-24 |
2021-12-30 |
Gilead Sciences, Inc. |
1'-cyano nucleoside analogs and uses thereof
|
|
WO2022047065A2
(en)
|
2020-08-27 |
2022-03-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
MX2024001184A
(es)
|
2021-07-28 |
2024-02-27 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
|
|
MX2024001185A
(es)
|
2021-07-28 |
2024-02-27 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades renales en mamiferos no humanos.
|
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
|
IL314031A
(en)
|
2021-12-30 |
2024-09-01 |
Newamsterdam Pharma B V |
Obicetrapib and sglt2 inhibitor combination
|
|
TW202525810A
(zh)
|
2022-03-02 |
2025-07-01 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
|
EP4531810A1
(en)
|
2022-05-25 |
2025-04-09 |
Boehringer Ingelheim Vetmedica GmbH |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
US20240307628A1
(en)
|
2023-03-06 |
2024-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
EP4701626A1
(en)
|
2023-04-24 |
2026-03-04 |
NewAmsterdam Pharma B.V. |
Amorphous obicetrapib and sglt2 inhibitor combination
|
|
WO2024240632A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|
|
KR20260019532A
(ko)
|
2023-05-24 |
2026-02-10 |
베링거잉겔하임베트메디카게엠베하 |
하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방
|